Oncternal Therapeutics Stock Analysis

Oncternal Stock Analysis Notes

About 15.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.93. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncternal Therapeutics recorded a loss per share of 13.43. The entity last dividend was issued on the 10th of June 2019. The firm had 1:20 split on the 8th of January 2024. Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. Oncternal Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Oncternal Therapeutics contact James Breitmeyer at 858 434 1113 or learn more at https://www.oncternal.com.

Oncternal Therapeutics Investment Alerts

Oncternal Therapeutics Upcoming and Recent Events

Oncternal Largest EPS Surprises

View All Earnings Estimates

Oncternal Stock Institutional Investors

Note, although Oncternal Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Oncternal Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 25.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncternal Therapeutics's market, we take the total number of its shares issued and multiply it by Oncternal Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Oncternal Profitablity

Management Efficiency

Oncternal Therapeutics has return on total asset (ROA) of (0.4948) % which means that it has lost $0.4948 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8675) %, meaning that it created substantial loss on money invested by shareholders. Oncternal Therapeutics' management efficiency ratios could be used to measure how well Oncternal Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.13 in 2024. Return On Capital Employed is likely to drop to -1.39 in 2024. Change To Liabilities is likely to gain to about 2.1 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 31.8 M in 2024.

Technical Drivers

As of the 25th of April, Oncternal Therapeutics holds the Risk Adjusted Performance of 0.0564, semi deviation of 4.29, and Coefficient Of Variation of 1312.76. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncternal Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down nineteen technical drivers for Oncternal Therapeutics, which can be compared to its competitors. Please check Oncternal Therapeutics variance, as well as the relationship between the value at risk and skewness to decide if Oncternal Therapeutics is priced some-what accurately, providing market reflects its current price of 8.55 per share. Given that Oncternal Therapeutics has jensen alpha of 0.3692, we recommend you to check out Oncternal Therapeutics's recent market performance to make sure the company can sustain itself at a future point.

Oncternal Therapeutics Price Movement Analysis

Oncternal Therapeutics Insider Trading Activities

Oncternal Therapeutics Predictive Daily Indicators

Oncternal Therapeutics Corporate Filings

Oncternal Therapeutics Forecast Models

Oncternal Therapeutics' time-series forecasting models are one of many Oncternal Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncternal Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Oncternal Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oncternal shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Oncternal Therapeutics. By using and applying Oncternal Stock analysis, traders can create a robust methodology for identifying Oncternal entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Oncternal analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Oncternal analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Oncternal Therapeutics stock analysis indicators help investors evaluate how Oncternal Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Oncternal Therapeutics shares will generate the highest return on investment. By understating and applying Oncternal Therapeutics stock analysis, traders can identify Oncternal Therapeutics position entry and exit signals to maximize returns.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Note that the Oncternal Therapeutics information on this page should be used as a complementary analysis to other Oncternal Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Oncternal Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.